Summary

[parkquartz18 Users]

parkquartz18 Users

• 

Offline

Show Posts
Show Stats

Posts:

0 (0 per day)

Age:

N/A

Date Registered:

2025-06-15, 11:21:14

Local Time:

2025-07-02, 22:26:05

Last Active:

2025-06-15, 16:24:30

Signature:

Blinatumomab is a first-in-class immunotherapy based on the bispecific T-cell engager (BiTE®) immune-oncology platform, which redirects CD3+ T ce